
Prevalence and epidemiological traits of HIV infections in populations with high-risk behaviours as revealed by genetic analysis of HBV

Y. KOJIMA^{1*}, T. KAWAHATA¹, H. MORI¹, K. FURUBAYASHI²,
Y. TANIGUCHI³, A. IWASA⁴, K. TANIGUCHI⁵, H. KIMURA⁶ AND J. KOMANO¹

¹ Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, Osaka, Japan

² Sonezaki Furubayashi Clinic, Osaka, Japan

³ Taiyuji-chou Taniguchi Clinic, Osaka, Japan

⁴ Iwasa Clinic, Osaka, Japan

⁵ Taniguchi Ladies Clinic, Osaka, Japan

⁶ Kimura Clinic, Osaka, Japan

Received 18 September 2012; Final revision 20 November 2012; Accepted 20 December 2012;
first published online 25 January 2013

SUMMARY

The prevalence and epidemiological traits of human immunodeficiency virus (HIV)/hepatitis B virus (HBV) infections in high-risk populations (HRPs) remained unclarified in Japan. We determined the prevalence of HIV, HBV and *Treponema pallidum* (TP) and the viral genotypes in HRPs who attended primary sexually transmitted infection (STI) clinics in Osaka province during 2006–2011. Of 7898 specimens, 133 (1·7%) were HIV positive, which was significantly higher than the figures reported by Japanese Red Cross (0·0019%) and public health centres (0·27%) in Japan. The frequency of HIV-1 subtype B was 88·7%, followed by CRF01_AE (2·3%) and C (0·8%), which were almost identical to the national trend. HBV seroprevalence was surprisingly high in the HIV-positive group (63·2%), which was significantly higher than that in the HIV-negative group (25·6%). By contrast, there was no statistical correlation between HIV and TP infection. Interestingly, the distinct HBV genotypes Ae and G were prevalent in the HIV-positive population (60·0% and 20·0%, respectively), although both were rarely detected during nationwide surveillance. The transmission of HIV and HBV appeared to occur largely within a closed community early in life. Of note, about one-quarter of HIV-positive cases would have remained untested if health professionals had not motivated individuals to undergo HIV testing. This is the first evidence-based assessment of HIV positivity and HIV/HBV co-infection in HRPs at primary STIs in Japan and the effect of the involvement of health professionals in the diagnosis of HIV infections in asymptomatic carriers. The genotyping of HBV provided valuable information for understanding HIV epidemical traits.

Key words: Epidemiology, hepatitis B, HIV disease (AIDS), sexually transmitted infections (STIs), syphilis (*T. pallidum* infection).

* Author for correspondence: Y. Kojima, Division of Virology, Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, 1-3-69, Nakamichi Higashinari-ku, Osaka 537-0025, Japan.
(Email: kojima@iph.pref.osaka.jp)

INTRODUCTION

In recent years, two devastating diseases, human immunodeficiency virus (HIV) and hepatitis viral infections, have received substantial global attention. More than 30 million people are living with HIV according to UNAIDS (<http://www.unaids.org/globalreport/default.htm>). The pandemic strain of HIV-1 group M has at least nine genetically distinct subtypes (or clades), including A, B, and C. Occasionally, two different subtypes yield a recombinant virus known as a circulating recombinant form (CRF), such as CRF01_AE. In Japan, the number of people living with HIV and AIDS has continued to increase, although the figures are relatively small compared to those from other countries. The precise rate of HIV prevalence in high-risk populations (HRPs) has not been assessed in Japan.

Over 350 million people worldwide are chronically infected with hepatitis B virus (HBV) according to the World Health Organization (WHO; <http://www.who.int/mediacentre/factsheets/fs204/en/>) [1]. HBV is classified into 10 genotypes (A–J). The global distribution of HBV genotypes indicates geographical divergence [2–6]. In Japan, it is estimated that one million people are carriers of HBV [7]. The major route of HBV infection has been mother-to-child transmission [8]. However, virtually no cases of mother-to-child HBV infection have been reported since nationwide measures were introduced to prevent mother-to-child transmission in 1986 [8]. In addition, the incidence of nosocomial infections has rarely been reported due to programmes operated by the Japanese Red Cross Society, which maximize the safety of blood transfusion products, and an HBV vaccination programme for health professionals [9]. However, the vaccination programme has not been standardized. Furthermore, no preventive measures have been taken to combat sexually transmitted HBV infection, which may accelerate the spread of HBV in young people.

HBV and HIV share similar transmission routes, so it is not surprising that there is a high frequency of co-infection. HIV/HBV co-infected individuals develop chronic hepatitis B at a higher rate than HBV mono-infected individuals and they have a high mortality rate [10, 11]. Furthermore, the approved anti-retroviral drugs emtricitabine (FTC), lamivudine (3TC), and tenofovir (TDF) also have antiviral activity against HBV [12]. It has been noted that the early diagnosis of HIV and HBV infection should

improve treatment outcome, and potentially HIV-infected individuals are encouraged to undergo HBV testing to ensure that they receive appropriate medical care.

The number of HIV-infected individuals continues to rise in Japan. This study aimed primarily at assessing the prevalence and the latest epidemiological trend of HIV and HBV infections in HRPs attending primary sexually transmitted infection (STI) clinics in Japan, which remain uncharacterized. Viral genotype analysis can provide insights into the epidemiology of viral infection. Thus, a molecular epidemiological study of HIV and HBV infections was conducted to determine the traits of HIV and HBV prevalence in HRPs, as well as an analysis of *Treponema pallidum* (TP) seroprevalence. We focused on HBV, rather than HCV, because the co-infection rate of HBV was significantly higher than that of HCV in HIV-positive individuals in Japan [13]. Moreover, individuals with blood clotting disorders treated with contaminated non-heated blood products, i.e. the majority of HCV/HIV co-infected individuals in Japan, were not included in this study [14]. Interestingly, HBV genotype analysis was more informative than the HIV subtype analysis for understanding the epidemiology of HRPs.

CASES AND METHODS

Specimens

During 2006–2011, 7898 cases were examined (5120 men, 2773 women, and five of unknown sex; mean age \pm s.d. = 33.3 ± 10.0 years; median 31 years). All attended primary STI clinics in Osaka province, Japan. Osaka has the second highest number of new HIV-infected individuals and AIDS patients (<http://idsc.nih.go.jp/iasr/32/380/tpc380.html>). The current study included individuals who were considered to be engaged in sexual activities carrying a high risk of HIV infection. We considered the following as high-risk behaviours: unprotected sex, having sex with multiple partners, men who have sex with men (MSM), and needle-sharing. None of the subjects reported a blood clotting disorder as a present medical history. For comparison purposes, an equal number of HIV-negative and HIV-positive cases was selected from the cases where medical professionals recommended HIV testing. The mean age \pm s.d. of this HIV-negative group was 37.2 ± 11.1 (Table 1).

Table 1. Summary of HIV-positive and HIV-negative populations investigated in the current study*

Category	HIV-positive (N=133)		HIV-negative† (N=133)		Statistical significance‡
	No. of cases	(%)	No. of cases	(%)	
Gender					
Male	132	(99.2)	127	(95.6)	
Female	1	(0.8)	6	(4.4)	
Age (yr)					
Mean ± s.d. [median]	33.1 ± 8.7 [32]		37.2 ± 11.1 [36]		<i>P</i> < 0.001
18–19	2	(1.5)	1	(0.8)	
20–29	51	(38.3)	34	(25.6)	
30–39	55	(41.4)	52	(39.1)	
40–49	18	(13.5)	24	(18)	
50–59	5	(3.8)	14	(10.5)	
60–69	2	(1.5)	6	(4.5)	
70–79	0	(0)	1	(0.8)	
Unknown	0	(0)	1	(0.8)	
Nationality					
Japanese	126	(94.7)	130	(97.7)	
Non-Japanese	1	(0.8)	0	(0)	
Unknown	6	(4.5)	3	(2.3)	
Sexual orientation					
Homosexual	97	(72.9)	8	(6)	
Heterosexual	5	(3.8)	0	(0)	
Bisexual	1	(0.8)	0	(0)	
Unknown	30	(22.6)	125	(94)	
Needle-sharing	0	(0)	0	(0)	

* Total number of cases studied was 7898. See the Cases and Methods section for details.

† An equal number of HIV-negative and HIV-positive cases were selected for comparison.

‡ Fisher's exact test between HIV-positive and HIV-negative groups.

Serology

An HIV screening test was performed using the Genedia HIV-1/2 mix particle agglutination (PA) and Serodia HIV-1/2 PA anti-HIV assay method (Fujirebio Inc., Japan). After screening for HIV-positive cases, confirmatory tests were performed using LAV Blot 1 and LAV Blot 2 (Bio-Rad, USA). Pepti-LAV 1/2 (Bio-Rad) was used for differentiation of HIV-1 and HIV-2 antibodies, if necessary. There were no cases of HIV-2 infection identified in this study. HIV antibody-negative cases were tested further by nucleic acid amplification testing (Amplicor HIV-1 Monitor test or COBAS[®] TaqMan[®] HIV-1 test, Roche Diagnostic Systems, Japan). HBV serological examinations were performed for the HBs antigen (Ag) using the Espline HBsAg kit (Fujirebio Inc.), anti-HBs antibody (Ab) using the Serodia anti-HBs PA kit (Fujirebio Inc.) and anti-HBcAb using the Mycell anti-HBc kit (Institute of Immunology Co. Ltd, Japan). TP Ab was tested by the Serodia TP PA test (Fujirebio Inc.).

Genetic analysis

After extracting RNA from HIV-positive serum using Isogen LS (Nippon Gene, Japan) or QIAamp UltraSens Virus kit (Qiagen, Germany), the env-C2V3 region of HIV-1 was amplified by RT-PCR using a one-step RNA PCR kit (TaKaRa, Japan) to determine the nucleic acid sequence as described previously [15]. Multiple alignment of the nucleic acid sequences from samples and reference strains (<http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html>) was performed using CLUSTAL W (DDBJ: DNA Data Bank of Japan). A phylogenetic analysis was performed to determine the HIV subtypes using the Genetyx-Mac v. 14 (Genetyx, Japan).

DNA was extracted from HBsAg-positive serum using a DNA Extractor kit (Wako Pure Chemical Industries Inc., Japan) or a QIAamp UltraSens Virus kit (Qiagen). Then the core gene of the HBV genome was amplified by nested PCR as described previously [16]. In brief, an initial PCR was performed to amplify a 617-bp fragment using the Core-Out-For and the

Core-Out-Rev primers, followed by a second PCR that amplified a 459-bp fragment using the 1868 and AS2330 primers. If these primers failed to amplify the fragment, the Core-Inn-For and Core-Inn-Rev primers were used in the initial PCR. The HBV genotypes were determined by phylogenetic analysis using the genomic sequences of reference strains (<http://jose.med.kuleuven.be/genotypetool/html/subtypeprocessshby.html>). In the HBV genetic analysis, we examined HIV-negative cases that were not included in the HIV-negative comparison group because the number of suitable HBV-positive cases was low.

Statistical analysis

Statistical analyses were performed using StatMate III (ATMS Co. Ltd, Japan). The mean ages of cases with HIV and HBV infections were compared using Fisher's exact test. Student's *t* test was used if the variances were homogenous, whereas Welch's *t* test or Cochran-Cox's *t* test were used if the variances were not homogenous. The rates of HBV and TP infections, and the correlation of HBV genotypes were analysed by χ^2 test.

Ethical considerations

Blood sampling was performed after obtaining informed consent following an explanation of the study. The identity of cases and some of the data were anonymized (age, sex, nationality, risk of transmission). The study was approved by the Ethical Review Board of Osaka Prefectural Institute of Public Health (approval number 0810-4 and 0810-5-2).

RESULTS

Analysis of HIV infection

Of the 7898 cases examined, 133 (1.7%) were confirmed as HIV-1 positive (Table 1). All were males with one exception. The mean age \pm s.d. of the HIV-positive cases was 33.1 ± 8.7 years (median 32 years). About 93% were aged 20–40 years and the number aged in their 20s, 30s and 40s was 51 (38.3%), 55 (41.4%) and 18 (13.5%), respectively. Compared to the HIV-negative group, the age of the HIV-positive group was significantly lower ($P < 0.001$, Fisher's exact test). The major risk factor was MSM (97/103 cases, 94.2%) according to the available risk data.

Five cases were heterosexual and one case was bisexual. Most were Japanese, with the exception of one French subject and two of unidentified nationality. It was reported that the rate of HIV positivity was 0.0019% (1.9 per 0.1 million) during 2006–2011 according to the Japanese Red Cross. The rate of positive HIV testing in public health centres throughout Japan was 0.27% (277/103,007) in 2010 (<http://idsc.nih.go.jp/iasr/32/380/tpc380.html>). Thus, the positive HIV rate in HRPs in the current study was significantly higher than previously reported ($P < 0.001$, χ^2 test).

Phylogenetic analysis of the HIV-1 env-C2V3 region showed that 118 cases (88.7%) were subtype B, three cases (2.3%) were CRF01_AE, and one case (0.8%) was subtype C. In Japan, 75–89.9% of new HIV-infected cases between 2003 and 2007 were subtype B, 6.1–13.9% were CRF01_AE, and 0.5–2.1% were subtype C (<http://idsc.nih.go.jp/iasr/31/366/tpc366.html>). These results suggested that the HRP viral subtype profile was indistinguishable from the national profile and that the HIV subtypes of HRPs are not unique in Japan.

Analysis of HBV infection

The number of past or present HBV infections in the HIV-positive group was 84 (84/133, 63.2%), whereas that in the HIV-negative group was 34 (34/133, 25.6%, Table 2). Overall, the positive HBV infection rate was significantly higher in the HIV-positive group than in the HIV-negative group ($P < 0.001$, χ^2 test). Of the HIV-positive cases, the number of HBsAg-positive cases was 15 (15/84, 17.9%). The positive HBsAg and HBcAb rates in the HIV-positive cases were 11.3% and 55.6%, respectively, while those in the HIV-negative cases were 1.5% and 21.1%, respectively. By contrast, the rates in blood donors during 2006–2011 were 0.073% and 0.23%, respectively, according to the Red Cross Blood Centre, which highlights the prevalence of HBV in the study population; this was significantly higher than that in healthy individuals, irrespective of HIV status ($P < 0.001$, χ^2 test). It was notable that the age of HIV-positive/HBV-positive cases (33.5 ± 8.8) was significantly lower than that of HIV-negative/HBV-positive cases (42.2 ± 12.1 , $P < 0.01$, Fisher's exact test). These data suggest that co-infection with HIV and HBV occurred relatively early in life in HRPs.

The genotype analyses revealed that of the 15 HIV-positive/HBsAg-positive cases, the majority of

Table 2. Summary of serological markers for HBV infection in HIV-positive and HIV-negative groups

Infection	Serological markers			HIV-positive group (N=133)		HIV-negative group (N=133)		Statistical significance*
	HBsAg	HBeAb	HBsAb	No. of cases	(%)	No. of cases	(%)	
Positive				84	(63.2)	34	(25.6)	$P < 0.001$
Present	+	-	-	3	(2.3)	0	(0)	n.s.
↓	+	+	-	12	(9)	2	(1.5)	$P < 0.05$
	-	+	-	27	(20.3)	9	(6.8)	$P < 0.01$
	-	+	+	35	(26.3)	17	(12.8)	$P < 0.01$
	-	n.t.	+	1	(0.8)	0	(0)	n.s.
Past	-	-	+	6	(4.5)	6	(4.5)	n.s.
Negative	-	-	-	49	(36.8)	99	(74.4)	$P < 0.001$

n.s., Not significant; n.t., not tested.

* χ^2 test between HIV-positive and HIV-negative groups.

Table 3. Analysis of HBV genotypes between HIV-positive and HIV-negative groups

HBV genotype	Current study (N=28)				Nationwide (N=720)*		Statistical significance†
	Total no. of cases	(%)	HIV positive (N=15)	HIV negative (N=13)	No. of cases	(%)	
A (Aa/Ae)	15	(53.6)	9 (0/9)	6 (1/5)	12	(1.7)	$P < 0.001$
B	0	(0)	0	0	88	(12.2)	n.s.
C	9	(32.1)	3	6	610	(84.7)	$P < 0.001$
D	0	(0)	0	0	3	(0.4)	n.s.
G	3	(10.7)	3	0	0	(0)	$P < 0.001$
Mixed	0	(0)	0	0	7	(1)	n.s.
Unknown	1	(3.6)	0	1	0	(0)	n.s.

n.s., Not significant.

* Orito *et al.* [29].

† χ^2 test between current study (total) and nationwide survey.

the HBV genotypes were Ae (9/15, 60.0%), followed by G (3/15, 20.0%), and C (3/15, 20.0%, Table 3). By contrast, the major HBV genotypes in the HIV-negative group were C (6/13, 46.2%) and Ae (5/13, 38.5%). Similarly, frequent detection of HBV genotype A in the Japanese HIV-1-positive MSM population was reported in Nagoya district although the study was not conducted at the primary STI clinic [15]. However, it should be noted that the previous study did not identify HBV genotype G in HIV-infected individuals [17]. It was previously reported that the nationwide prevalence of HBV/A, B, C, D and mixed genotypes during chronic hepatitis B in Japan was 1.7%, 12.2%, 84.7%, 0.4% and 1.0%, respectively [18]. This indicates that the overall HBV genotype profile of HRPs was distinct from other HBV-positive populations ($P < 0.001$, χ^2 test).

Analysis of TP infection

We also investigated the prevalence of TP to determine whether the low HBV prevalence was unique to HIV-negative subjects. The results of the TP Ab test showed that 44.4% of HIV-positive (59/133) and 48.9% of HIV-negative (65/133) cases were TP Ab-positive (Table 4). These values were significantly higher than the Red Cross Blood Centre's data for 2006–2011 (0.13%, $P < 0.001$, χ^2 test), indicating that the target population of our study was indeed at high risk of STIs. It was interesting to observe that, unlike HBV infections, the rate of TP Ab positivity was not significantly different between the HIV-positive and HIV-negative groups, suggesting that the transmission of HIV is correlated with HBV, but not with TP.

Table 4. Analysis of HBV and TP infection rates between HIV-positive and HIV-negative groups

Category*	HIV-positive group (N = 133)		HIV-negative group (N = 133)		Statistical significance†
	No. of cases	(%)	No. of cases	(%)	
TP positive	59	(44.4)	65	(48.9)	n.s.
HBV positive	39	(29.3)	26	(19.5)	n.s.
HBV negative	20	(15.0)	39	(29.3)	<i>P</i> < 0.05
TP negative	74	(55.6)	68	(51.1)	n.s.
HBV positive	45	(33.8)	8	(6.0)	<i>P</i> < 0.001
HBV negative	29	(21.8)	60	(45.1)	<i>P</i> < 0.01

TP, *Treponema pallidum*; n.s., not significant.

* HBV-positive cases include both present and past infection (please see Table 2).

† χ^2 test between HIV-positive and HIV-negative groups.

DISCUSSION

This is the first laboratory test-based surveillance study to determine the rate of HIV positivity and HIV/HBV co-infection in HRP at primary STI clinics in Japan. The prevalence of HIV in HRP attending primary STI clinics during 2006–2011 in Osaka province was 1.7%, which was surprisingly higher than we expected. The seroprevalence of HBV in HIV-positive individuals was 63.2%. HBV genotype analyses suggested that HIV was transmitted within a specific community, mainly the MSM population, in which distinct HBV genotypes were prevalent. HIV transmission was linked closely with HBV, whereas TP infection was not strongly associated with HIV prevalence. These epidemiological traits of HIV infection were identified by analysing HBV genotype. It has been suggested that healthcare workers should encourage individuals who engage in high-risk behaviors to have their HIV serostatus tested at primary STI clinics. However, the effect of this advice has been difficult to evaluate. It was notable that 32/133 HIV-positive cases (24.1%) received HIV testing based on the recommendations of health professionals, which demonstrates that active consultation with healthcare workers can facilitate earlier diagnosis of HIV infection. This makes it possible to diagnose HIV infection during the asymptomatic phase, which provides an opportunity for appropriate treatment and the prevention of unknowingly transmitting HIV/HBV to sex partners.

Syphilis is a STI that is caused by TP, which is distributed globally. TP and HIV share similar transmission routes and syphilis may increase the risk of HIV transmission by 2–5 times [19]. The clinical symptoms, diagnosis, and management of syphilis

differ for HIV-infected and HIV-uninfected patients [20–23]. In the USA, the rates of primary and secondary syphilis have been increasing steadily since 2001 in the MSM population [24]. In addition, 20–60% of new syphilis cases involved co-infection with HIV [25–28]. Thus, it is recommended that all syphilis cases undergo HIV testing in the USA. In Japan, it is reported that around 50% of HIV-infected individuals are TP seropositive, which is consistent with the findings of the current study. However, in contrast to the findings in the USA, the rates of TP positivity were similar in HIV-positive and HIV-negative groups. This is probably because the basal rate of TP infection was sufficiently high in this HRP to mask the TP-HIV linkage. It remains an open question whether the prevalence of TP in the HRP examined in our study has unique characteristics that contributed to these observations.

HBV genotypes B and C are the two main types of chronic hepatitis B in Japan (96.9%) [29]. However, it was reported recently that HBV genotype Ae is increasing gradually, particularly in urban areas, due to homosexual intercourse [18, 29–32]. An analysis of the responses to questionnaires sent to 372 hospitals across Japan in 2006 suggested that 70.8% of HIV-positive individuals were co-infected with HBV during homosexual intercourse [14]. Thus, it is likely that the subjects involved in the current study might be responsible for this increase in HBV genotype Ae.

Many studies have suggested that HBV genotypes can influence the clinical course, the response to interferon and nucleotide analogue therapy, and the rate of becoming fulminant [18, 30, 33–36]. HBV genotype Ae infections elicit a lower immune response because of their slow viral dynamics, which means that these infections appear to be more persistent, and

more likely to become chronic, than infection with other genotypes [18, 30]. Genotype G is an extremely rare genotype, which usually appears as a co-infection with genotype A, although little is known about its pathogenicity [6, 35, 37–40]. It would be beneficial to investigate the clinical course of HBV infection further, particularly genotypes Ae and G, in HIV-infected individuals. Low HBV-prevalence countries, including Japan, have not yet introduced universal hepatitis B vaccinations. A ‘selective’ vaccination policy may be considered where a vaccination could be provided to HRPs. It may be possible to advise individuals with high-risk behaviours about STIs at the same time they receive HBV vaccinations.

ACKNOWLEDGMENTS

This research was supported in part by a grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan and Daido Life Welfare Foundation, Local health-and-welfare research support. We thank Dr Toru Otake for critical reading of the manuscript.

DECLARATION OF INTEREST

None.

REFERENCES

1. Lee WM. Hepatitis B virus infection. *New England Journal of Medicine* 1997; **337**: 1733–1745.
2. Arauz-Ruiz P, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *Journal of General Virology* 2002; **83**: 2059–2073.
3. Yu H, et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype ‘I’. *PLoS ONE* 2010; **5**: e9297.
4. Norder H, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; **47**: 289–309.
5. Tatematsu K, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *Journal of Virology* 2009; **83**: 10538–10547.
6. Kato H, et al. Hepatitis B virus genotype G is an extremely rare genotype in Japan. *Hepatology Research* 2004; **30**: 199–203.
7. Tanaka J, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. *Intervirology* 2011; **54**: 185–195.
8. Yoshikawa A, et al. Effect of selective vaccination on a decrease in the rate of hepatitis B virus-positive Japanese first-time blood donors. *Transfusion Medicine* 2009; **19**: 172–179.
9. Mitsui T, et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. *Hepatology* 1989; **10**: 324–327.
10. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *Journal of Infectious Diseases* 1991; **163**: 1138–1140.
11. Bonacini M, et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. *AIDS* 2004; **18**: 2039–2045.
12. Menne S, et al. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. *Antimicrobial Agents and Chemotherapy* 2008; **52**: 3617–3632.
13. Gatanaga H, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. *Antiviral Research* 2007; **75**: 75–82.
14. Koike K, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. *Hepatology Research* 2008; **38**: 310–314.
15. Kojima Y, et al. Recent diversity of human immunodeficiency virus type 1 in individuals who visited sexually transmitted infection-related clinics in Osaka, Japan. *Journal of Infection and Chemotherapy* 2008; **14**: 51–55.
16. Vitale F, et al. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection? *Journal of Medical Virology* 2008; **80**: 577–582.
17. Fujisaki S, et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfecting with HIV-1 in Japan. *Journal of Clinical Microbiology* 2011; **49**: 1017–1024.
18. Ozasa A, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* 2006; **44**: 326–334.
19. Reynolds SJ, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. *Sexually Transmitted Infections* 2006; **82**: 121–126.
20. Hicks CB, et al. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. *Annals of Internal Medicine* 1987; **107**: 492–495.
21. Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. *Annals of Internal Medicine* 1990; **113**: 872–881.
22. Horowitz HW, et al. Brief report: cerebral syphilitic gumma confirmed by the polymerase chain reaction in a

- man with human immunodeficiency virus infection. *New England Journal of Medicine* 1994; **331**: 1488–1491.
23. **Augenbraun M, et al.** Treponemal specific tests for the serodiagnosis of syphilis. Syphilis and HIV Study Group. *Sexually Transmitted Diseases* 1998; **25**: 549–552.
 24. **CDC.** Primary and secondary syphilis – United States, 2002. *Morbidity and Mortality Weekly Report* 2003; **52**: 1117–1120.
 25. **CDC.** Primary and secondary syphilis among men who have sex with men – New York City, 2001. *Morbidity and Mortality Weekly Report* 2002; **51**: 853–856.
 26. **CDC.** Primary and secondary syphilis – United States, 2003–2004. *Morbidity and Mortality Weekly Report* 2006; **55**: 269–273.
 27. **Taylor MM, et al.** Use of the serologic testing algorithm for recent HIV seroconversion (STARHS) to identify recently acquired HIV infections in men with early syphilis in Los Angeles County. *Journal of Acquired Immune Deficiency Syndromes* 2005; **38**: 505–508.
 28. **Kerani RP, et al.** Rising rates of syphilis in the era of syphilis elimination. *Sexually Transmitted Diseases* 2007; **34**: 154–161.
 29. **Orito E, et al.** Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001; **34**: 590–594.
 30. **Suzuki Y, et al.** Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *Journal of Medical Virology* 2005; **76**: 33–39.
 31. **Yotsuyanagi H, et al.** Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *Journal of Medical Virology* 2005; **77**: 39–46.
 32. **Kobayashi M, et al.** Change of hepatitis B virus genotypes in acute and chronic infections in Japan. *Journal of Medical Virology* 2008; **80**: 1880–1884.
 33. **Yuen MF, et al.** Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. *Journal of Hepatology* 2004; **41**: 119–125.
 34. **Watanabe K, et al.** Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. *Journal of Gastroenterology and Hepatology* 2005; **20**: 441–449.
 35. **Janssen HL, et al.** Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005; **365**: 123–129.
 36. **Kobayashi M, et al.** Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. *Journal of Medical Virology* 2006; **78**: 60–67.
 37. **Stuyver L, et al.** A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *Journal of General Virology* 2000; **81**: 67–74.
 38. **Kato H, et al.** Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). *Journal of Virology* 2002; **76**: 6131–6137.
 39. **Bottecchia M, et al.** Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. *BMC Microbiology* 2008; **8**: 11.
 40. **Osiowy C, et al.** Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. *Journal of General Virology* 2008; **89**: 3009–3015.